Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 19, 2015
Previous Article Next Article

Development of an enzymatic pretargeting strategy for dual-modality imaging

Author affiliations

Abstract

A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag–Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.

Graphical abstract: Development of an enzymatic pretargeting strategy for dual-modality imaging

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Dec 2014, accepted on 03 Feb 2015 and first published on 04 Feb 2015


Article type: Communication
DOI: 10.1039/C4CC10265G
Author version
available:
Download author version (PDF)
Chem. Commun., 2015,51, 4055-4058

  •   Request permissions

    Development of an enzymatic pretargeting strategy for dual-modality imaging

    J. C. Knight, M. Mosley, M. R. L. Stratford, H. T. Uyeda, H. A. Benink, M. Cong, F. Fan, S. Faulkner and B. Cornelissen, Chem. Commun., 2015, 51, 4055
    DOI: 10.1039/C4CC10265G

Search articles by author

Spotlight

Advertisements